Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

NCT06480383 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

705

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Anxiety Disorder

Interventions

DRUG: ITI-1284 10 mg
DRUG: ITI-1284 20 mg
DRUG: Placebo

Sponsor

Intra-Cellular Therapies, Inc.